NI200900021A - Inhibidor de quinasa - Google Patents

Inhibidor de quinasa

Info

Publication number
NI200900021A
NI200900021A NI200900021A NI200900021A NI200900021A NI 200900021 A NI200900021 A NI 200900021A NI 200900021 A NI200900021 A NI 200900021A NI 200900021 A NI200900021 A NI 200900021A NI 200900021 A NI200900021 A NI 200900021A
Authority
NI
Nicaragua
Prior art keywords
kinase inhibitor
prodrugs
compound
solvates
compounds
Prior art date
Application number
NI200900021A
Other languages
English (en)
Spanish (es)
Inventor
A Gillespy Timothy
Eynott Paul
M Allen Elizabeth
T Yu Kin
Zilberstein Asher
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NI200900021A publication Critical patent/NI200900021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NI200900021A 2006-09-11 2009-02-17 Inhibidor de quinasa NI200900021A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82516806P 2006-09-11 2006-09-11

Publications (1)

Publication Number Publication Date
NI200900021A true NI200900021A (es) 2010-01-29

Family

ID=39032357

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900021A NI200900021A (es) 2006-09-11 2009-02-17 Inhibidor de quinasa

Country Status (32)

Country Link
US (2) US8658649B2 (enExample)
EP (1) EP2094708B1 (enExample)
JP (1) JP5161237B2 (enExample)
KR (1) KR101443056B1 (enExample)
CN (2) CN103804383A (enExample)
AR (1) AR062745A1 (enExample)
AU (1) AU2007296592B8 (enExample)
BR (1) BRPI0716781A2 (enExample)
CA (1) CA2663175C (enExample)
CL (1) CL2007002617A1 (enExample)
CO (1) CO6160236A2 (enExample)
CR (1) CR10636A (enExample)
DK (1) DK2094708T3 (enExample)
ES (1) ES2437318T3 (enExample)
GT (1) GT200900055A (enExample)
HN (1) HN2009000455A (enExample)
IL (1) IL197381A (enExample)
MA (1) MA30781B1 (enExample)
MX (1) MX2009002616A (enExample)
MY (1) MY148107A (enExample)
NI (1) NI200900021A (enExample)
NO (1) NO20091265L (enExample)
NZ (1) NZ575496A (enExample)
PE (1) PE20081372A1 (enExample)
PT (1) PT2094708E (enExample)
RU (1) RU2440352C2 (enExample)
TN (2) TN2009000049A1 (enExample)
TW (1) TWI399379B (enExample)
UA (1) UA94622C2 (enExample)
UY (1) UY30584A1 (enExample)
WO (1) WO2008033798A2 (enExample)
ZA (1) ZA200901073B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372908T3 (es) * 2008-02-25 2012-01-27 F. Hoffmann-La Roche Ag Inhibidores de la pirrolopirazina quinasa.
PL2250172T3 (pl) 2008-02-25 2012-01-31 Hoffmann La Roche Pirolopirazynowe inhibitory kinazy
JP5284377B2 (ja) 2008-02-25 2013-09-11 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼ阻害剤
MX2010008198A (es) 2008-02-25 2010-08-23 Hoffmann La Roche Inhibidores de cinasa de pirrolopirazina.
ATE517107T1 (de) 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitoren
RU2010141560A (ru) * 2008-03-10 2012-04-20 Санофи-Авентис (Fr) Лечение офтальмологических заболеваний
FR2929851B1 (fr) * 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es) 2008-12-03 2010-07-27 Sanofi Aventis Tratamiento para la glomerulonefritis
CA2745262A1 (en) 2008-12-04 2010-06-10 Sanofi Crystalline forms
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
SG181857A1 (en) 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CA2798970A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
JP2013529204A (ja) * 2010-05-20 2013-07-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロ［２，３−ｂ］ピラジン−７−カルボキサミド誘導体とＪＡＫ及びＳＹＫ及び阻害剤としてのそれらの使用
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
MX2015002181A (es) * 2012-08-21 2015-05-07 Hoffmann La Roche Pirrolo[2,3-b]pirazinas como inhibidores de syk.
CA2919479C (en) * 2013-07-31 2017-08-22 Gilead Sciences, Inc. Syk inhibitors
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116969927B (zh) * 2023-06-07 2024-03-19 中南民族大学 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1998022457A1 (en) 1996-11-19 1998-05-28 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6312835B1 (en) 1997-02-13 2001-11-06 Queen's University At Kingston Luminescent compounds and methods of making and using same
ES2202827T3 (es) 1997-03-19 2004-04-01 ABBOTT GMBH & CO. KG Pirrolo(2,3-d)pirimidinas y su uso como inhibidores de la tirosina kinasa.
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
DE69830409T2 (de) 1997-08-05 2006-01-26 Pfizer Products Inc., Groton 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten
RU2219178C2 (ru) 1997-10-20 2003-12-20 Ф.Хоффманн-Ля Рош Аг Бициклические производные, фармацевтическая композиция на их основе и промежуточные соединения
JP4741725B2 (ja) 1998-03-06 2011-08-10 メタベイシス・セラピューティクス・インコーポレーテッド リン含有化合物のための新規なプロドラッグ
CA2326185A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051596A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP4549534B2 (ja) 1998-05-26 2010-09-22 中外製薬株式会社 複素環を有するインドール誘導体及びモノ又はジアザインドール誘導体
NZ510587A (en) 1998-09-18 2003-11-28 Abbott Gmbh & Co 4-aminopyrrolopyrimidines as kinase inhibitors
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CN100379734C (zh) * 1999-12-24 2008-04-09 阿文蒂斯药物有限公司 氮杂吲哚类化合物
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) * 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
CA2402516A1 (en) * 2000-03-20 2001-09-27 Roopa Rai Non-amidine containing protease inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6673923B2 (en) * 2000-05-03 2004-01-06 Tularik Inc. Pyrazole antimicrobial agents
EP1294718A2 (en) 2000-06-14 2003-03-26 Warner-Lambert Company Llc 6,5-fused bicyclic heterocycles
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
US20040082365A1 (en) * 2002-07-18 2004-04-29 Celerica Ltd Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
AU2005269387A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
WO2006052712A1 (en) 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor
CN101098872B (zh) * 2004-11-22 2012-09-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders

Also Published As

Publication number Publication date
IL197381A (en) 2013-11-28
JP2010502767A (ja) 2010-01-28
NZ575496A (en) 2011-09-30
AR062745A1 (es) 2008-12-03
DK2094708T3 (da) 2014-01-27
EP2094708A2 (en) 2009-09-02
UY30584A1 (es) 2008-05-02
PE20081372A1 (es) 2008-11-27
MA30781B1 (fr) 2009-10-01
KR101443056B1 (ko) 2014-09-22
HN2009000455A (es) 2012-02-13
PT2094708E (pt) 2014-01-07
RU2440352C2 (ru) 2012-01-20
TWI399379B (zh) 2013-06-21
IL197381A0 (en) 2009-12-24
CA2663175C (en) 2012-03-13
TN2009000050A1 (en) 2010-08-19
MY148107A (en) 2013-02-28
US20100035884A1 (en) 2010-02-11
CL2007002617A1 (es) 2008-05-16
CR10636A (es) 2009-03-20
AU2007296592B2 (en) 2011-12-15
TW200829590A (en) 2008-07-16
UA94622C2 (en) 2011-05-25
BRPI0716781A2 (pt) 2014-11-18
CA2663175A1 (en) 2008-03-20
ZA200901073B (en) 2009-12-30
KR20090063214A (ko) 2009-06-17
WO2008033798A2 (en) 2008-03-20
AU2007296592A1 (en) 2008-03-20
US8658649B2 (en) 2014-02-25
WO2008033798A3 (en) 2008-05-15
CO6160236A2 (es) 2010-05-20
NO20091265L (no) 2009-04-03
ES2437318T3 (es) 2014-01-10
TN2009000049A1 (en) 2010-08-19
AU2007296592B8 (en) 2012-01-12
CN103804383A (zh) 2014-05-21
CN101511838A (zh) 2009-08-19
MX2009002616A (es) 2009-03-24
US20140142110A1 (en) 2014-05-22
EP2094708B1 (en) 2013-10-23
GT200900055A (es) 2010-07-28
RU2009113615A (ru) 2010-10-20
JP5161237B2 (ja) 2013-03-13

Similar Documents

Publication Publication Date Title
NI200900021A (es) Inhibidor de quinasa
NI201000059A (es) Inhibidores de la cinasa c-fms.
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
NI200900031A (es) Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos.
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
DOP2009000257A (es) Inhibidores de cinasa p70 s6
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
DOP2009000159A (es) Inhibidores de la poli(adp-ribosa) polimerasa
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
CR11333A (es) cis-IMIDAZOLINAS QUIRALES
SV2010003472A (es) Compuestos de pirazol
UY28745A1 (es) Nuevos compuestos
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
ATE400567T1 (de) Kinaseinhibitoren
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
TNSN08191A1 (en) Kinase inhibitors
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1